The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
American Society of Clinical Oncology.Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol.1997; 15(8): 2996–3018.
2.
CardenalF., Lopez-CabrerizoM P., AntonA.Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol.1999; 17: 12–8.
3.
CrinoL., ScagliottiG.V., RicciS.Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol.1999; 17: 3522–30.
4.
SandlerA.B., NemunaitisJ., DenhamC.Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol.2000; 18: 122–30.
5.
AbrattR P., SandlerA., CrinoL.Combined cisplatin and gemcitabine for non-small cell lung cancer: Influence of scheduling on toxicity and drug delivery. Semin Oncol.1998; 25(suppl 9): 35–43.
6.
AbrattR P., HackingD.J., GoedhalsL.Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma. Semin Oncol.1997; 24(suppl 8) S8–18–23.
7.
CrinoL., ScagliottiG., MarangoloM.Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol.1997; 15: 297–303.
8.
ComellaP., FrasciG., PanzaN.Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol.2000; 18: 1451–7.
9.
CastellanoD., LianesP., Paz-AresL.A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol.1998; 9: 457–9.
10.
ShepherdF.A., CormierY., BurkesR.Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol.1997; 24(suppl 8)S8–27–30.
11.
LippeP., TummarelloD., MonterubbianesiM.C.Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study. Ann Oncol.1999; 10: 217–21.
12.
AntonA., Diaz-FernandezN., Gonzalez-LarribaJ.L.Phase II trail assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer.1998; 22: 139–48.
13.
KroepJR, PetersG.J., van MoorselC.J.A.Gemcitabine-cisplatin: A schedule finding study. Ann Oncol.1999; 10: 1503–10.
14.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
15.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm.1999; 56: 729–64.
16.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Oncology.1997; 11: 57–89.
17.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
18.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50: 147–58.
American Society of Clinical Oncology.American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.1994; 12: 2471–508.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
23.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
24.
HensleyM.L., SchuchterL.M., LindleyC.American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol.1999; 17: 3333–55.
25.
KintzelP.E., DorrR T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
26.
VempatyH., SrinivasS.Cisplatin in elderly. Proc Am Soc Clin Oncol.1999; 18: 607a.
27.
VenookA.P., EgorinM.J., RosnerG.L.Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol.2000; 18: 2780–7.
